The clinical and biological features of a series of immunophenotypic variant of B-CLL

Lilla Cro, Andrea Ferrario, Marta Lionetti, Francesco Bertoni, Nadia Zucal N, Lucia Nobili, Sonia Fabris, Katia Todoerti, Agostino Cortelezzi, Andrea Guffanti, Maria Goldaniga, Luigi Marcheselli, Antonino Neri, Giorgio Lambertenghi-Deliliers, Luca Baldini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48%) and 55/93 patients with CLL (59%) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.

Original languageEnglish
Pages (from-to)120-129
Number of pages10
JournalEuropean Journal of Haematology
Volume85
Issue number2
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Trisomy
Splenomegaly
Gene Expression Profiling
Lymphocytes
Mutation
Survival
Serum
Therapeutics

Keywords

  • B-cell chronic lymphocytic leukaemia
  • FISH analysis
  • IgV gene mutations
  • immunophenotype
  • ZAP-70 expression

ASJC Scopus subject areas

  • Hematology

Cite this

The clinical and biological features of a series of immunophenotypic variant of B-CLL. / Cro, Lilla; Ferrario, Andrea; Lionetti, Marta; Bertoni, Francesco; Zucal N, Nadia; Nobili, Lucia; Fabris, Sonia; Todoerti, Katia; Cortelezzi, Agostino; Guffanti, Andrea; Goldaniga, Maria; Marcheselli, Luigi; Neri, Antonino; Lambertenghi-Deliliers, Giorgio; Baldini, Luca.

In: European Journal of Haematology, Vol. 85, No. 2, 08.2010, p. 120-129.

Research output: Contribution to journalArticle

Cro, Lilla ; Ferrario, Andrea ; Lionetti, Marta ; Bertoni, Francesco ; Zucal N, Nadia ; Nobili, Lucia ; Fabris, Sonia ; Todoerti, Katia ; Cortelezzi, Agostino ; Guffanti, Andrea ; Goldaniga, Maria ; Marcheselli, Luigi ; Neri, Antonino ; Lambertenghi-Deliliers, Giorgio ; Baldini, Luca. / The clinical and biological features of a series of immunophenotypic variant of B-CLL. In: European Journal of Haematology. 2010 ; Vol. 85, No. 2. pp. 120-129.
@article{2c684dc35e6445a6ae09618345fa69b1,
title = "The clinical and biological features of a series of immunophenotypic variant of B-CLL",
abstract = "Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48{\%}) and 55/93 patients with CLL (59{\%}) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.",
keywords = "B-cell chronic lymphocytic leukaemia, FISH analysis, IgV gene mutations, immunophenotype, ZAP-70 expression",
author = "Lilla Cro and Andrea Ferrario and Marta Lionetti and Francesco Bertoni and {Zucal N}, Nadia and Lucia Nobili and Sonia Fabris and Katia Todoerti and Agostino Cortelezzi and Andrea Guffanti and Maria Goldaniga and Luigi Marcheselli and Antonino Neri and Giorgio Lambertenghi-Deliliers and Luca Baldini",
year = "2010",
month = "8",
doi = "10.1111/j.1600-0609.2010.01454.x",
language = "English",
volume = "85",
pages = "120--129",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - The clinical and biological features of a series of immunophenotypic variant of B-CLL

AU - Cro, Lilla

AU - Ferrario, Andrea

AU - Lionetti, Marta

AU - Bertoni, Francesco

AU - Zucal N, Nadia

AU - Nobili, Lucia

AU - Fabris, Sonia

AU - Todoerti, Katia

AU - Cortelezzi, Agostino

AU - Guffanti, Andrea

AU - Goldaniga, Maria

AU - Marcheselli, Luigi

AU - Neri, Antonino

AU - Lambertenghi-Deliliers, Giorgio

AU - Baldini, Luca

PY - 2010/8

Y1 - 2010/8

N2 - Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48%) and 55/93 patients with CLL (59%) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.

AB - Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48%) and 55/93 patients with CLL (59%) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.

KW - B-cell chronic lymphocytic leukaemia

KW - FISH analysis

KW - IgV gene mutations

KW - immunophenotype

KW - ZAP-70 expression

UR - http://www.scopus.com/inward/record.url?scp=77954719731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954719731&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2010.01454.x

DO - 10.1111/j.1600-0609.2010.01454.x

M3 - Article

C2 - 20408870

AN - SCOPUS:77954719731

VL - 85

SP - 120

EP - 129

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -